Tyra Biosciences Inc. has described indazole compounds acting as fibroblast growth factor receptors (FGFR) inhibitors reported to be useful for the treatment of cancer.
Tuojie Biotech (Shanghai) Co. Ltd. has divulged cyclin-dependent kinase 2 (CDK2)/cyclin E inhibitors reported to be useful for the treatment of cancer and immunological disorders.
Uppthera Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding agent coupled to serine/threonine-protein kinase PLK1 (STPK13) targeting moiety through a linker, acting as novel PLK1 protein degradation-inducing compounds with use for the treatment of cancer and neurological disorders.
Blueprint Medicines Corp. has disclosed EGFR (L858R/T790M/C797S triple mutant) and/or EGFR (exon 19 deletion mutant) inhibitors reported to be useful for the treatment of cancer.
Induction of immunogenic cell death (ICD) in cancer has been proposed as a promising strategy to elicit potent adaptive immune responses against tumor-associated antigens, potentially overcoming the limited efficacy of immunotherapy in some patients and tumor types. Since type I interferon (IFN) is a key modulator of ICD in antitumor responses, researchers at the University of California, San Diego are investigating how to expand the IFN effect to promote ICD responses in cancer cells.
Upregulation of C-X-C motif chemokine ligand 1 (CXCL1) has been validated in patients with colorectal cancer (CRC), but the mechanism behind CXCL1 affecting CRC tumor cell progression is not clear. Gene-editing techniques were used to investigate the impact of CXCL1 knockout and overexpression in CRC cells.
Previous studies have demonstrated that increased expression of the granulocyte-macrophage colony-stimulating factor (GM-CSF) correlated with poor prognosis in patients with cholangiocarcinoma (CCA) and pancreatic ductal adenocarcinoma (PDAC). In the current study, a research team at the University of Rochester Medical Center aimed to assess the impact of blocking GM-CSFR signaling in CCA and PDAC.
Cholangiocarcinoma (CCA) is a lethal hepatobiliary cancer with poor outcome; thus, new therapeutic approaches are needed. It is known that tyrosine-protein kinase LCK activates Yes-associated protein (YAP), which is a well-known known oncogene in CCA. Researchers have hypothesized LCK as a potential therapeutic target in CCA.
Ferroptosis, an iron-dependent cell death mechanism driven by unrestricted lipid peroxidation in the plasma membrane, is an emerging therapeutic target for cancer treatment. The lipid metabolism determines ferroptotic responses, but the lipid remodeling mechanism that determines sensitivity to ferroptosis and the function of phospholipid transporters in this mechanism remain unclear. To shed light on these questions, scientists from Guangzhou Medical University and colleagues have systematically measured the expression of 49 genes encoding phospholipid transporters (phospholipid scramblases, flippases and floppases) during ferroptosis.
RSS
